Atopic dermatitis (eczema) trials in China

In China 57 Also abroad 251

57 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis
Where
Nanjing
Age
18 years and over
People
80
Run by
Zhongda Hospital
See details and how to joinNCT07573735
Phase 1Enrolling by invitation
A Phase I Clinical Trial to Evaluate CU-10101 Unguent
Where
Shanghai
Age
18 years to 65 years
People
64
Run by
Cutia Therapeutics（Wuxi）Co.,Ltd
See details and how to joinNCT06744569
No phaseEnrolling by invitation
A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features
Where
Shanghai
Age
18 years to 65 years
People
50
Run by
Xi Tan
See details and how to joinNCT06999941
No phaseTaking people
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
Where
Beijing
Age
18 years and over
People
1,000
Run by
Chengdu Kangnuoxing Biopharma,Inc.
See details and how to joinNCT07544862
Phase 1Taking people
A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants
Where
Shanghai
Age
18 years to 70 years
People
90
Run by
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07488065
Phase 1Not yet taking people in China
A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis
Where
Hangzhou
Age
18 years to 75 years
People
16
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07549984
Phase 3Not yet taking people in China
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
Where
Shenyang
Age
12 years to 17 years
People
180
Run by
Shanghai Mabgeek Biotech.Co.Ltd
See details and how to joinNCT07540442
Phase 2Taking people
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
Where
Guangzhou
Age
18 years to 75 years
People
75
Run by
Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07211542
Phase 2Taking people
A Clinical Study to Evaluate SM17 for Atopic Dermatitis
Where
Beijing
Age
18 years to 70 years
People
200
Run by
SinoMab BioScience Ltd
See details and how to joinNCT07445919
Phase 2Not yet taking people in China
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
Where
Beijing, Binzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Jinan, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Shiyan, Suzhou, Tangshan, Tianjin, Wuhan, Xi'an, Yinchuan, Zhengzhou, Zhenjiang
Age
18 years to 75 years
People
160
Run by
Dermavon Holdings Limited
See details and how to joinNCT07465120
Phase 2Taking people
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
Where
Beijing
Age
18 years to 75 years
People
120
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07399067
Phase 2Taking people
A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
Where
Chengdu
Age
18 years to 75 years
People
111
Run by
Chengdu Zenitar Biomedical Technology Co., Ltd
See details and how to joinNCT07193589
Phase 3Taking people
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
Where
Beijing, Jinhua, Nanchang
Age
12 years to 17 years
People
180
Run by
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
See details and how to joinNCT07042126
Phase 2Taking people
A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
Where
Beijing
Age
18 years and over
People
246
Run by
Keymed Biosciences Co.Ltd
See details and how to joinNCT07230483
Phase 2Not yet taking people in China
A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
Where
Hangzhou, Shenyang
Age
18 years to 75 years
People
184
Run by
Jiangsu Simcere Pharmaceutical Co., Ltd.
See details and how to joinNCT07175233
Phase 3Enrolling by invitation
A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.
Where
Hangzhou
Age
18 years to 75 years
People
460
Run by
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
See details and how to joinNCT07180511
Phase 3Taking people
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
Where
Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Handan, Hangzhou, Hefei, Hohhot, Jinan, Jingzhou, Jining, Jiujiang, Kunming, Liuzhou, Luoyang, Nanchang, Nanjing, Ningbo, Qingdao, Sanmenxia, Shanghai, Shaoguan, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuhu, Xiamen, Xi'an, Xi’an, Yancheng, Yiwu, Yuncheng, Zhengzhou
Age
18 years to 75 years
People
552
Run by
Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT06775860
Phase 3Taking people
Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
Where
Shenyang
Age
18 years to 75 years
People
360
Run by
Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT06880276
Phase 2Taking people
Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
Where
Beijing
Age
18 years to 75 years
People
200
Run by
Keymed Biosciences Co.Ltd
See details and how to joinNCT06947980
Phase 1Taking people
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis
Where
Suzhou
Age
18 years to 65 years
People
9
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07015762
Phase 3Not yet taking people in China
A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
Where
Beijing
Age
2 years to 12 years
People
240
Run by
Keymed Biosciences Co.Ltd
See details and how to joinNCT07106372
Phase 1Taking people
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
Where
Beijing
Age
18 years to 75 years
People
102
Run by
Shanghai Qilu Pharmaceutical Research and Development Center LTD
See details and how to joinNCT06946641
Phase 2Not yet taking people in China
Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
Where
Hangzhou
Age
18 years to 65 years
People
120
Run by
Zhejiang Kanova Biopharmaceutical Co., LTD
See details and how to joinNCT07054736
No phaseTaking people
A Clinical Study Evaluating the Application of La Roche-Posay's New B5 Multi-Effect Soothing and Repairing Cream on Individuals With Facial Atopic Dermatitis
Where
Shanghai
Age
18 years to 65 years
People
76
Run by
ChinaNorm
See details and how to joinNCT07022288
Phase 3Taking people
A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis
Where
Shenyang
Age
12 years to 75 years
People
472
Run by
Prime Gene Therapeutics Co., Ltd.
See details and how to joinNCT06587685